Lexitas Pharma Services is expanding its position in ophthalmology clinical research through the acquisition of Erie Retina Research, CASExERIE, and the assets of Element Erie: Imaging & Reading Center, a deal that significantly broadens the company’s capabilities in retinal clinical trials, surgical innovation, and centralized imaging analysis.
The acquisitions deepen Lexitas’ specialization in ophthalmology at a time when retinal disease has become one of the most active and commercially important segments in biopharmaceutical development, driven by advances in gene therapy, biologics, surgical devices, and long-duration treatments targeting chronic vision disorders.
Financial terms of the transaction were not disclosed.
Lexitas, a portfolio company of private equity firm QHP Capital, said Erie Retina Research will continue operating as a wholly owned subsidiary. The transaction also folds in CASExERIE, an ophthalmic innovation and surgical training hub, along with Element Erie’s retinal imaging and reading center operations.
The combined platform is designed to create a more vertically integrated retina research ecosystem spanning patient recruitment, clinical trial operations, surgical training, device development, image grading, and scientific consulting.
That integration reflects broader shifts underway across the contract research organization market, where sponsors increasingly seek specialized partners capable of handling complex therapeutic areas with greater operational coordination and scientific depth.
Retina research has become especially demanding operationally because many ophthalmology trials rely heavily on imaging interpretation, specialized procedures, highly targeted patient populations, and precise endpoint analysis. Companies capable of integrating those functions under a single operational framework are becoming more valuable to drug developers seeking to accelerate timelines and reduce execution risk.
Lexitas said the deal strengthens its ability to support retinal pharmaceutical and device studies across both early- and late-stage development.
The addition of Element Erie’s imaging and reading center capabilities is particularly strategic. Centralized image analysis has become a critical component of ophthalmic clinical trials, especially in diseases such as age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders where imaging endpoints often determine treatment efficacy assessments.
By integrating imaging interpretation directly into its broader clinical infrastructure, Lexitas is attempting to reduce fragmentation across trial execution while improving consistency in data evaluation.
The acquisition also brings Dr. David Almeida into Lexitas as chief retina strategy officer. Almeida, a vitreoretinal surgeon and clinician-scientist who led Erie Retina Research and founded CASExERIE, has built one of the more active retina-focused research centers in the country, with more than 40 ongoing clinical studies and over 1,000 patients enrolled in research programs.
His addition gives Lexitas greater scientific and procedural expertise at a time when retinal therapies are evolving rapidly beyond traditional anti-VEGF injections toward gene editing, sustained-delivery implants, advanced biologics, and surgical interventions.
The ophthalmology market has become increasingly attractive to both pharmaceutical companies and investors because retinal diseases often involve chronic treatment pathways, aging patient populations, and significant unmet medical need tied to preserving vision and independence.
At the same time, competition among CROs specializing in ophthalmology has intensified as sponsors seek faster enrollment, more reliable endpoint analysis, and access to highly specialized investigators.
Lexitas Chief Executive Officer Jeanne Hecht said the acquisitions would help create a more coordinated retina research infrastructure capable of improving trial predictability and accelerating therapeutic development.
The deal also aligns with QHP Capital’s broader strategy of building scaled healthcare services platforms in specialized areas benefiting from long-term clinical and demographic tailwinds.
For Lexitas, the acquisitions extend the company beyond traditional CRO operations into a more integrated ophthalmic development platform that combines operational execution with scientific consulting, imaging analytics, procedural training, and device evaluation capabilities.
Agenda Health served as financial advisor to Erie Retina Research on the transaction.